Skip to content

Public FDA record

Z-0847-2021: visby medical COVID-19 Test kit *** An in vitro diagnostic for the qualitative detection of SARS-CoV-2 -

Recall record Z-0847-2021 for VISBY MEDICAL INC. View source facts, labeled dates, and the original FDA record.

FDA identifier
Z-0847-2021
Company in FDA record
VISBY MEDICAL INC
FDA record creation date
Jan 12, 2021
First observed by MedTech Watch
Nov 16, 2026
Latest observed content change
Nov 16, 2026
Recall classification
Class II

Reason stated in the source

Two issues: 1) 5 Lots were found to have incorrect labeling on the outer box stating that the product is CLIA Waived. 2) 3 Lots contain a kit component that expires prior to the expiration date on the test kits.

Source facts

Action
On or about 12/07/2020, the firm contacted via telephone its customers and sent an "URGENT *** Recall and Field Corrective Action" Notification Letter via overnight courier informing them of the two issues pertaining to 5 specific lots of their test kits. The issues are: 1) Expiration Date: Visby COVID-19 Test kits lots LN20100067, LN20100148, LN20110040, have an expiration date on the outer kit boxes that matches the expiration date of the Visby COVID-19 devices contained in the foil pouch test kits. However, the outer kit boxes also contains Visby Dilution Kits with a shorter expiration date. The expiration dates of the affected test kits, Visby COVID-19 devices and Visby Dilution Kits are listed in the following table. While the Visby Dilution Kit packaging is labeled with the correct expiration date, the test kit labeling extends beyond the expiration date of the buffer within the Dilution Kit. The buffer should not be used beyond the expiration date on the Visby Dilution Kit label. 2) CLIA Waiver labeling: The outer kit boxes of all Visby COVID-19 Test kits shipped prior to December 4, 2020, were incorrectly labeled as CLIA waived. The Visby Medical COVID-19 test authorization is limited to use in CLIA moderate and high complexity laboratories. The image below reflects the incorrect labeling. The package insert and other labeling included with the Visby test kit correctly identify these test kits as for use in CLIA moderate and high complexity laboratories. The health risks associated with the two issues: A. Expiration Date: If any patients were tested after the buffer expiration date, there is a potential increased risk of false negative test results. Tests performed prior to the expiration date of the Visby Dilution Buffer are valid and unaffected by this issue. B. CLIA Waiver labeling: There is no impact to patient results related to the incorrect CLIA Waiver labeling. Customer s are instructed to: A. Expiration Date: For Device Lots affected by
Initiated
2020-12-05
Root cause
Process control
Terminated
2022-01-07
Distribution
U.S. Nationwide distribution including in the states of CA, DC, FL, GA, MD, MN, MT, VA, and WA. O.U.S.: None
Recall number
Z-0847-2021
Recall status
Terminated
CDRH record ID
185131
FDA record created
2021-01-12
Recall event number
87049

Source facts and excerpts are reproduced for research. Dates retain their source meanings. “First observed” describes collection, not FDA publication or product launch.

Recall classification is supplied only when the recall number matches an enforcement record. Recall class and device class are different fields. Several recall records may belong to one recall event.

Useful context

Device classifications

FDA dataset:

Last successful check: Nov 22, 2026

Source classifications may change.

510(k) clearances

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset monthly.

Recall records

FDA dataset:

Last successful check: Nov 22, 2026

FDA publishes this dataset weekly.

Keep this research moving.

Follow ten competitors and ten product codes. Get matching changes in your dashboard and a weekly brief, for $49/month.

Start a 14-day free trial ↗